2006年培美曲塞研究新进展  

Advances in clinical research of Pemetrexed on 2006

作　　者：马飞[1] 李树婷[1] 孙燕[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院,北京100021

出　　处：《癌症进展》2006年第6期523-528,共6页Oncology Progress

摘　　要：培美曲塞是一种多靶点的抗代谢类药物,目前已经在70余个国家批准上市,用于治疗恶性胸膜间皮瘤和非小细胞肺癌。在过去的两年间,在多种肿瘤中开展了多项有关培美曲塞的临床研究,部分研究结果在今年的ASCO年会上报道,我们对这些资料进行了汇总。Pemetrexed is a muhitargeted antimetabolite that has shown activity in malignant pleural mesothelioma and NSCLC, which has been approved in more than 70 countries. During the past 2 years, a lot of clinical trials on Pemetrexed have been conducted in subjects with several kinds of cancer, and the results of many trials were reported on 2006 ASCO annual meeting. We undertook a review of the published literature on this topic.

关 键 词：抗代谢类抗肿瘤药物 培美曲塞 临床试验 

分 类 号：R730.53[医药卫生—肿瘤]